Table 2. Growth Inhibition Data of Complexes 1–3, 7–9, and 10–12 against HeLa Cells and Corresponding Tumor Specificities.

	drug	HeLa IC50 (μM)	lymph (resting) IC50 (μM)	lymph (stimulated) IC50 (μM)	tumor specificity (TS)
PPh3 derivatives	1	2.56 ± 0.12	9.05 ± 3.50	8.55 ± 3.37	3.4
	2	2.63 ± 0.10	9.53 ± 3.18	8.63 ± 3.77	3.5
	3	2.56 ± 0.17	13.98 ± 10.50	5.08 ± 2.48	3.7
dppp derivatives	7	3.07 ± 0.48	7.05 ± 2.02	5.02 ± 1.72	1.9
	8	6.96 ± 0.51	6.13 ± 2.92	2.94 ± 0.91	0.7
	9	3.38 ± 0.30	18.48 ± 3.88	8.16 ± 4.10	3.9
dpph derivatives	10	0.51 ± 0.08	18.89 ± 5.66	6.68 ± 3.40	25.0
	11	0.14 ± 0.01	18.23 ± 15.90	1.38 ± 0.39	70.5
	12	4.04 ± 0.49	37.74 ± 12.60	30.25 ± 11.06	8.4
	cis-platin	0.45 ± 0.09